180 related articles for article (PubMed ID: 37468950)
1. Proton therapy and oral mucositis in oral & oropharyngeal cancers: outcomes, dosimetric and NTCP benefit.
Nangia S; Gaikwad U; Noufal MP; Sawant M; Wakde M; Mathew A; Chilukuri S; Sharma D; Jalali R
Radiat Oncol; 2023 Jul; 18(1):121. PubMed ID: 37468950
[TBL] [Abstract][Full Text] [Related]
2. NTCP reduction for advanced head and neck cancer patients using proton therapy for complete or sequential boost treatment versus photon therapy.
Jakobi A; Stützer K; Bandurska-Luque A; Löck S; Haase R; Wack LJ; Mönnich D; Thorwarth D; Perez D; Lühr A; Zips D; Krause M; Baumann M; Perrin R; Richter C
Acta Oncol; 2015; 54(9):1658-64. PubMed ID: 26340301
[TBL] [Abstract][Full Text] [Related]
3. Spot scanning proton arc therapy reduces toxicity in oropharyngeal cancer patients.
de Jong BA; Battinelli C; Free J; Wagenaar D; Engwall E; Janssens G; Langendijk JA; Korevaar EW; Both S
Med Phys; 2023 Mar; 50(3):1305-1317. PubMed ID: 36373893
[TBL] [Abstract][Full Text] [Related]
4. Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: A case-matched control analysis.
Holliday EB; Kocak-Uzel E; Feng L; Thaker NG; Blanchard P; Rosenthal DI; Gunn GB; Garden AS; Frank SJ
Med Dosim; 2016; 41(3):189-94. PubMed ID: 27158021
[TBL] [Abstract][Full Text] [Related]
5. A Quantitative Clinical Decision-Support Strategy Identifying Which Patients With Oropharyngeal Head and Neck Cancer May Benefit the Most From Proton Radiation Therapy.
Brodin NP; Kabarriti R; Pankuch M; Schechter CB; Gondi V; Kalnicki S; Guha C; Garg MK; Tomé WA
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):540-552. PubMed ID: 30496877
[TBL] [Abstract][Full Text] [Related]
6. Impact of setup and range uncertainties on TCP and NTCP following VMAT or IMPT of oropharyngeal cancer patients.
Hamming-Vrieze O; Depauw N; Craft DL; Chan AW; Rasch CRN; Verheij M; Sonke JJ; Kooy HM
Phys Med Biol; 2019 Apr; 64(9):095001. PubMed ID: 30921775
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of acute toxicities and patient reported outcomes between intensity-modulated proton therapy (IMPT) and volumetric modulated arc therapy (VMAT) for the treatment of oropharyngeal cancer.
Manzar GS; Lester SC; Routman DM; Harmsen WS; Petersen MM; Sloan JA; Mundy DW; Hunzeker AE; Amundson AC; Anderson JL; Patel SH; Garces YI; Halyard MY; McGee LA; Neben-Wittich MA; Ma DJ; Frank SJ; Whitaker TJ; Foote RL
Radiother Oncol; 2020 Jun; 147():64-74. PubMed ID: 32234612
[TBL] [Abstract][Full Text] [Related]
8. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Oropharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.
Youssef I; Yoon J; Mohamed N; Zakeri K; Press RH; Chen L; Gelblum DY; McBride SM; Tsai CJ; Riaz N; Yu Y; Cohen MA; Dunn LA; Ho AL; Wong RJ; Michel LS; Boyle JO; Singh B; Kriplani A; Ganly I; Sherman EJ; Pfister DG; Fetten J; Lee NY
JAMA Netw Open; 2022 Nov; 5(11):e2241538. PubMed ID: 36367724
[TBL] [Abstract][Full Text] [Related]
9. Radiobiological model-based approach to determine the potential of dose-escalated robust intensity-modulated proton radiotherapy in reducing gastrointestinal toxicity in the treatment of locally advanced unresectable pancreatic cancer of the head.
Raturi VP; Hojo H; Hotta K; Baba H; Takahashi R; Rachi T; Nakamura N; Zenda S; Motegi A; Tachibana H; Ariji T; Motegi K; Nakamura M; Okumura M; Hirano Y; Akimoto T
Radiat Oncol; 2020 Jun; 15(1):157. PubMed ID: 32571379
[TBL] [Abstract][Full Text] [Related]
10. Early clinical outcomes of helical tomotherapy/intensity-modulated proton therapy combination in nasopharynx cancer.
Park SG; Ahn YC; Oh D; Noh JM; Ju SG; Kwon D; Jo K; Chung K; Chung E; Lee W; Park S
Cancer Sci; 2019 Sep; 110(9):2867-2874. PubMed ID: 31237050
[TBL] [Abstract][Full Text] [Related]
11. Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin's lymphoma. Assessment of risk of toxicity and secondary cancer induction.
Scorsetti M; Cozzi L; Navarria P; Fogliata A; Rossi A; Franceschini D; De Rose F; Franzese C; Carlo-Stella C; Santoro A
Radiat Oncol; 2020 Jan; 15(1):12. PubMed ID: 31931861
[TBL] [Abstract][Full Text] [Related]
12. Using a reduced spot size for intensity-modulated proton therapy potentially improves salivary gland-sparing in oropharyngeal cancer.
van de Water TA; Lomax AJ; Bijl HP; Schilstra C; Hug EB; Langendijk JA
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e313-9. PubMed ID: 21708427
[TBL] [Abstract][Full Text] [Related]
13. Dosimetric and radiobiological impact of intensity modulated proton therapy and RapidArc planning for high-risk prostate cancer with seminal vesicles.
Rana S; Cheng C; Zhao L; Park S; Larson G; Vargas C; Dunn M; Zheng Y
J Med Radiat Sci; 2017 Mar; 64(1):18-24. PubMed ID: 27741379
[TBL] [Abstract][Full Text] [Related]
14. Helical tomotherapy vs. intensity-modulated proton therapy for whole pelvis irradiation in high-risk prostate cancer patients: dosimetric, normal tissue complication probability, and generalized equivalent uniform dose analysis.
Widesott L; Pierelli A; Fiorino C; Lomax AJ; Amichetti M; Cozzarini C; Soukup M; Schneider R; Hug E; Di Muzio N; Calandrino R; Schwarz M
Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1589-600. PubMed ID: 21167651
[TBL] [Abstract][Full Text] [Related]
15. Probability of normal tissue complications for hematologic and gastrointestinal toxicity in postoperative whole pelvic radiotherapy for gynecologic malignancies using intensity-modulated proton therapy with robust optimization.
Yoshimura T; Yamada R; Kinoshita R; Matsuura T; Kanehira T; Tamura H; Nishioka K; Yasuda K; Taguchi H; Katoh N; Kobashi K; Hashimoto T; Aoyama H
J Radiat Res; 2024 May; 65(3):369-378. PubMed ID: 38499489
[TBL] [Abstract][Full Text] [Related]
16. Identification of Patient Benefit From Proton Therapy for Advanced Head and Neck Cancer Patients Based on Individual and Subgroup Normal Tissue Complication Probability Analysis.
Jakobi A; Bandurska-Luque A; Stützer K; Haase R; Löck S; Wack LJ; Mönnich D; Thorwarth D; Perez D; Lühr A; Zips D; Krause M; Baumann M; Perrin R; Richter C
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1165-1174. PubMed ID: 26194685
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome after pencil beam scanning proton therapy and dysphagia/xerostomia NTCP calculations of proton and photon radiotherapy delivered to patients with cancer of the major salivary glands.
Walser MA; Bachmann N; Kluckert J; Köthe A; Tully C; Leiser D; Lomax AJ; Bizzocchi N; Langendijk JA; Weber DC
Br J Radiol; 2023 Aug; 96(1148):20220672. PubMed ID: 37129312
[TBL] [Abstract][Full Text] [Related]
18. A Model-Based Approach to Predict Short-Term Toxicity Benefits With Proton Therapy for Oropharyngeal Cancer.
Rwigema JM; Langendijk JA; Paul van der Laan H; Lukens JN; Swisher-McClure SD; Lin A
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):553-562. PubMed ID: 30625409
[TBL] [Abstract][Full Text] [Related]
19. IMPT of head and neck cancer: unsupervised machine learning treatment planning strategy for reducing radiation dermatitis.
Padannayil NM; Sharma DS; Nangia S; Patro KC; Gaikwad U; Burela N
Radiat Oncol; 2023 Jan; 18(1):11. PubMed ID: 36639667
[TBL] [Abstract][Full Text] [Related]
20. Multifield optimization intensity modulated proton therapy for head and neck tumors: a translation to practice.
Frank SJ; Cox JD; Gillin M; Mohan R; Garden AS; Rosenthal DI; Gunn GB; Weber RS; Kies MS; Lewin JS; Munsell MF; Palmer MB; Sahoo N; Zhang X; Liu W; Zhu XR
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):846-53. PubMed ID: 24867532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
